Published online Nov 26, 2020. doi: 10.4330/wjc.v12.i11.571
Peer-review started: August 21, 2020
First decision: October 5, 2020
Revised: October 21, 2020
Accepted: October 30, 2020
Article in press: October 30, 2020
Published online: November 26, 2020
Processing time: 97 Days and 4.7 Hours
Complications of transcatheter aortic valve implantation (TAVI) procedures include bleeding, vascular complications, and strokes. These complications are often associated with the type of access used. Access can be primary or secondary. Few studies have been published on the effect of secondary access on outcomes.
The objective of this meta-analysis is to investigate if transradial secondary access (TRSA) has fewer complications than transfemoral or vice versa, with the hope of reducing complications in TAVI procedures related to access.
This systematic review aims to compare outcomes between transradial vs transfemoral secondary access (TFSA).
A systematic search was conducted using major databases (EMBASE, PubMed, Cochrane Central, Google Scholar), which resulted in 5 studies that met criteria for study selection. Outcomes of interest were 30-d rates each of major/life-threatening bleeding, vascular complications, strokes, and mortality. All 5 studies were observational. Adjusted or matched data were used if reported.
A total of 5065 patients underwent TAVI, with 1453 patients (28.7%) having undergone TRSA and 3612 patients (71.3%) TFSA. Irrespective of the site of primary access, the odds of having major or life-threatening bleeding were 60% lower in the TRSA group than the TFSA group (P < 0.00001). The odds of having major vascular complications were 52% lower in the TRSA group (P < 0.0001) with no difference in minor vascular complications between the 2 groups. Similarly, the odds of mortality in 30d after the procedure were 41% lower (P = 0.006) and the odds of stroke were 54% lower (P = 0.001) in the TRSA group than the TFSA group.
TRSA appears to be a safer alternative to the TFSA in TAVI procedures.
Our findings need to be confirmed in randomized clinical trials, which should minimize selection bias and both measured and unmeasured confounding.